RMC-6772

RMC-6772 appears to be an investigational small-molecule oncology compound associated with Revolution Medicines, but public high-confidence information specific to this exact code name is extremely limited. Based on Revolution Medicines' broader pipeline focus, it is likely intended as a targeted anticancer agent within the company's RAS-pathway-centered discovery efforts; however, I could not verify a precise mechanism of action, target profile, formulation, route, or active clinical development program for this exact molecule from reliable public sources. Because the exact identity and pharmacology are not clearly established in accessible sources, the drug should be treated as an uncharacterized investigational code name pending primary-source confirmation.